1. Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
   Charlotte LT Jørgensen et al, 2013, BMC Cancer CrossRef
2. Nucleotide metabolism, oncogene-induced senescence and cancer
   Katherine M. Aird et al, 2015, Cancer Letters CrossRef
3. Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer
   Y-Y Hsieh et al, 2016, Cell Death Discovery CrossRef
4. Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma
   Jiewei Chen et al, 2017, BMC Cancer CrossRef
5. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I–III Non-Small Cell Lung Cancer
   Francesco Grossi et al, 2015, Disease Markers CrossRef
6. Ribonucleotide Reductase Subunit M2 Predicts Survival in Subgroups of Patients with Non-Small Cell Lung Carcinoma: Effects of Gender and Smoking Status
   Vei Mah et al, 2015, PLOS ONE CrossRef
7. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells
   Pei-Ming Yang et al, 2020, Biomolecules CrossRef